澳大利亚前列腺癌手术与放疗的全国性当代分析
该研究基于澳大利亚Medicare报销数据,分析2002-2016年前列腺癌根治性前列腺切除(RP)、近距离放疗及2012-2016年外照射放疗(EBRT)的趋势。结果显示RP和低剂量率近距离放疗在2002-2009年增加后下降,2016年分别为124和6.9/10万男性;EBRT保持稳定但下降5%至42/10万;75-84岁组RP率增加108%。
要点
- 2009年后前列腺癌治疗总体减少,主要因年轻患者治疗减少和近距离放疗使用下降。
- RP是最常用治疗,在>65岁男性中使用上升,75-84岁组RP率增加108%。
- 2012-2016年RP下降15%,低剂量率近距离放疗下降58%,EBRT下降5%至42/10万。
核心结论
- 全国索赔数据显示2009年以来前列腺癌治疗减少,主要归因于年轻患者治疗减少和近距离放疗使用下降。
- RP最常用,且在>65岁男性中使用上升。
研究设计与样本
- 基于澳大利亚Medicare Benefits Schedule数据的 population-level 分析,提取RP和近距离放疗(2002-2016)及EBRT(2012-2016)数据。
- 治疗率按私治患者整体和前列腺癌人群计算,分析年龄和地理趋势。
主要发现
- RP和低剂量率近距离放疗在2002-2009年增加,但2016年分别降至124和6.9/10万男性。
- <65岁男性中下降更显著。
- 2012年起RP下降15%,低剂量率近距离放疗下降58%,EBRT保持稳定但下降5%至42/10万男性(2016年)。
- 75-84岁年龄组总体治疗增加,RP率增加108%。
临床怎么用
- 临床实践中应关注前列腺癌治疗模式的年龄和地理差异,尤其是年轻患者治疗减少和老年患者RP增加的趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize national clinical practice trends in the treatment of prostate cancer (PCa) in Australia. PATIENTS AND METHODS: Population-level data were extracted from existing Medicare Benefits Schedule data for radical prostatectomy (RP) and brachytherapy (2002-2016), as well as external beam radiotherapy (EBRT; 2012-2016). Treatment rates were calculated relative to whole and PCa populations among privately treated patients. Overall age-related and geographical trends were analysed. RESULTS: The use of RP and low-dose-rate (LDR) brachytherapy increased between 2002 and 2009, but subsequently decreased to 124 and 6.9 per 100 000 men, respectively, in 2016. More dramatic decreases were observed for men aged <65 years. From 2012, rates of RP (15% drop) and LDR brachytherapy (58% drop) decreased, while the use of EBRT remained steady, falling by 5% to 42 per 100 000 men in 2016. Overall treatment increased in the age group 75-84 years, with the rate of RP increasing by 108%. CONCLUSION: National claims data indicate there has been a reduction in PCa treatment since 2009, which is mostly attributable to a reduction in the treatment of younger patients and reduced use of brachytherapy. RP is most commonly used and its use is rising in men aged >65 years.
引用
- Roberts MJ, Papa N, Perera M, et al. A contemporary, nationwide analysis of surgery and radiotherapy treatment for prostate cancer. BJU Int. 2019. PMID: 31486575. doi:10.1111/bju.14773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。